Lab Diagnosis of Syphilis: The Testing Algorithm and How to Interpret Results

A patient's blood test comes back with a reactive RPR. Does that single result mean the patient has syphilis? Not yet. On its own, a reactive RPR could be a true infection, or a false positive from pregnancy or another illness. To answer the question, you need a second test of a different kind, and you need to know how to read the two results together.

Syphilis is diagnosed in an unusual way, because Treponema pallidum cannot be grown in the laboratory. Instead, diagnosis rests on a two-step logic: screen with one kind of antibody test, confirm with another. This page is about that logic, how the algorithm works, and how to interpret each combination of results, rather than the procedure of any single test, which is covered on the individual test pages.

Introduction

Syphilis is a sexually transmitted infection caused by Treponema pallidum. It is called "the great imitator" because it mimics many other diseases, which is exactly why laboratory diagnosis matters: you often cannot tell syphilis from the clinical picture alone.

Diagnosing syphilis has one defining challenge: T. pallidum cannot be grown on any laboratory medium. There is no culture to fall back on. So diagnosis relies on two strategies: seeing the organism directly in a lesion (possible only in early syphilis, when a lesion is present), and, far more often, detecting antibodies in the blood (serology). Serology is the mainstay, and understanding how the tests fit together is the key skill.

For the organism itself and the stages of disease, see the Treponema pallidum and syphilis page. This page is about how the diagnosis is made.

Direct detection: seeing or detecting the organism

When an active lesion is present in early (primary or secondary) syphilis, the organism can be detected directly.

• Dark-field microscopy: the classic method. Fluid from a chancre or secondary lesion is examined under dark-field, where the live, motile spirochetes can be seen directly. It works only with an active, organism-rich lesion and needs an experienced observer. The full method is on the dark-field microscopy page.

Figure: Darkfield micrograph of Treponema pallidum (source: CDC)

• Direct fluorescent antibody (DFA): fluorescent-labeled antibodies bind T. pallidum in a smear, making it visible under a fluorescence microscope. Unlike dark-field, it does not need live organisms, so the specimen does not have to be examined immediately.
• PCR and other nucleic acid tests: detect T. pallidum DNA from a lesion swab, CSF, or blood, and are especially useful very early, before antibodies have appeared. Several molecular formats exist (PCR and various isothermal methods); they are mostly used in reference or research settings rather than routine practice.

Direct detection is powerful when a lesion is available, but most syphilis is diagnosed after lesions have healed or in later stages, which is why serology is the mainstay.

Serology: the screen-then-confirm logic

Serology is the mainstay of syphilis diagnosis. It uses two different kinds of antibody test, and the whole logic rests on understanding why you need both.

Non-treponemal tests (the screen)

These detect antibodies against cardiolipin, a lipid released from host cells damaged by the infection (and from the treponeme itself), not against the organism directly.

• Examples: VDRL, RPR, and TRUST.
• Strengths: cheap, fast, and quantitative. The titer rises and falls with disease activity, so these tests are used both to screen and to monitor the response to treatment (a falling titer means treatment is working).
• Weakness: because they detect an indirect marker, they produce false positives in pregnancy, other infections, and autoimmune disease. So a reactive non-treponemal test must always be confirmed.

Treponemal tests (the confirmation)

These detect antibodies against T. pallidum itself, using the organism or its components as the antigen.

• Examples: TPHA, FTA-ABS, and TP-PA.
• Strength: highly specific, so they confirm a reactive screening test.
• Weakness: they stay positive for life after infection, treated or not. So they cannot tell active from past infection, and cannot be used to monitor treatment.

Why you need both

Each test covers the other's weakness. The non-treponemal test is a cheap, sensitive screen that follows treatment but gives false positives; the treponemal test is specific and confirms, but stays positive forever. Neither alone answers the question. Together they do.

The classic algorithm (traditional):

1. Screen with a non-treponemal test (VDRL or RPR).
2. If reactive, confirm with a treponemal test (TPHA or FTA-ABS).
3. Follow the response to treatment with the non-treponemal titer (it should fall).

Many laboratories now use a reverse algorithm, screening first with an automated treponemal test (because it can be automated) and then using a non-treponemal test to sort out active from past infection. Either way, the underlying principle is the same: one test to screen, a different kind to confirm, and the non-treponemal titer to follow treatment.

How to interpret the results

The answer comes from the combination of the two tests, not either alone. This is the reasoning the hub owns.

Two points that make the table make sense:

• A falling non-treponemal titer after treatment (for example, a fourfold drop) indicates successful treatment. A rising titer suggests reinfection or treatment failure. This is why the non-treponemal test, not the treponemal one, is used for follow-up.
• A serological diagnosis confirms treponemal infection but does not tell you the stage of disease, and, on its own, may not separate past from current infection. The clinical picture is always part of the interpretation.

One caution worth knowing: a very high antibody level can occasionally make a non-treponemal test falsely non-reactive unless the serum is diluted, the prozone phenomenon. Suspect it when the clinical picture strongly suggests syphilis (for example, florid secondary syphilis) but the screen is negative.

The syphilis tests at a glance

How to remember

Can't culture it, so test the antibodies. T. pallidum will not grow in the lab, so diagnosis is by seeing it (dark-field, early lesions only) or, mostly, by serology. No culture. That single fact explains the whole approach.

Non-treponemal screens and follows; treponemal confirms and stays. The two-test logic in one line. Non-treponemal (VDRL/RPR) is cheap, screens, and its titer follows treatment, but it false-positives. Treponemal (TPHA/FTA-ABS) is specific, confirms, and stays positive for life, so it can't follow treatment. Each fixes the other's weakness.

Read the pair, not the single. One reactive test answers nothing. Reactive-plus-reactive means syphilis; reactive-plus-negative-treponemal means false positive; negative-plus-reactive-treponemal usually means past treated infection. The combination is the answer.

Titer falls, treatment worked. Because the non-treponemal titer tracks disease activity, a fourfold fall means the treatment is working, and a rise means reinfection or failure. This is why you follow treatment with the non-treponemal test, never the treponemal one.

Key exam facts in one table

Where students get confused

One positive test is not a diagnosis. A reactive VDRL or RPR alone can be a false positive; a positive treponemal test alone can be old, treated infection. You must read the two tests together.

Which test follows treatment. The non-treponemal test (VDRL/RPR) follows treatment because its titer falls with cure. The treponemal test (TPHA/FTA-ABS) stays positive for life, so it is useless for monitoring. Students often mix this up.

A positive treponemal test after cure is expected. It does not mean the patient still has active syphilis or that treatment failed. Treponemal antibodies persist for life. Judge cure by the falling non-treponemal titer.

False positives are on the non-treponemal test. Because non-treponemal tests detect an indirect marker (cardiolipin), they are the ones that false-positive in pregnancy, other infections, and autoimmune disease. The treponemal test is used precisely to sort these out.

Serology does not give the stage. A positive result confirms infection but does not tell you whether it is primary, secondary, latent, or tertiary. Staging comes from the clinical picture.

The prozone trap. A strongly suspected secondary syphilis with a negative non-treponemal screen may be a prozone false negative from very high antibody levels. Diluting the serum reveals the true positive.

References

1. Larsen, S. A., Steiner, B. M., & Rudolph, A. H. (1995). Laboratory diagnosis and interpretation of tests for syphilis. Clinical Microbiology Reviews, 8(1), 1–21. https://doi.org/10.1128/CMR.8.1.1
2. Tille, P. M. (2022). Bailey & Scott's Diagnostic Microbiology (15th ed.). Elsevier.
3. Centers for Disease Control and Prevention. (current). Syphilis: Laboratory Testing. https://www.cdc.gov/std/syphilis/
4. Madigan, M. T., Bender, K. S., Buckley, D. H., Sattley, W. M., & Stahl, D. A. (2021). Brock Biology of Microorganisms (16th ed.). Pearson.